Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised, double-blind, placebo-controlled, cross-over pilot study using nabilone for symptomatic relief in patients with Huntington's disease
ISRCTN ISRCTN16782845
ClinicalTrials.gov identifier
Public title A randomised, double-blind, placebo-controlled, cross-over pilot study using nabilone for symptomatic relief in patients with Huntington's disease
Scientific title
Acronym N/A
Serial number at source Sponsor 583; Eudract test 0000632-21
Study hypothesis That nabilone will have a beneficial effect on movement and psychiatric symptoms in patients with Huntington's disease
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised double blind placebo controlled crossover group trial
Countries of recruitment United Kingdom
Disease/condition/study domain Huntington's disease
Participants - inclusion criteria Competent patients with a clinical diagnosis of Huntington's disease over 18
Participants - exclusion criteria 1. Under 18
2. Known allergy to cannabinoids
3. Liver dysfunction
4. Personal or family history of psychosis
5. Heart disease or hypertension
6. Pregnant or lactating
Anticipated start date 01/09/2005
Anticipated end date 01/12/2006
Status of trial Completed
Patient information material
Target number of participants 40
Interventions Nabilone or placebo for 5 weeks, 5 week washout period cross over to nabilone or placebo for 5 weeks
Primary outcome measure(s) Motor symptoms rated using the motor scale from the UHDRS
Secondary outcome measure(s) Psychiatric symptoms rated using the behavioural assessment of the UHDRS and the NPI
Sources of funding Cambridge Laboratories (UK) - hold the European marketing rights for nabilone
Trial website
Publications
Contact name Dr  Hugh  Rickards
  Address Queen Elizabeth Psychiatric Hospital
Vincent Drive
Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2QZ
  Country United Kingdom
  Tel +44 (0)121 678 2019
  Fax +44 (0)121 678 2079
  Email hugh.rickards@bsmht.nhs.uk
Sponsor Birmingham and Solihull Mental Health Trust (UK)
  Address Uffculme Centre
Queensbridge Road
Moseley
  City/town Birmingham
  Zip/Postcode B13 8QY
  Country United Kingdom
  Tel +44 (0)121 678 2731
  Fax +44 (0)121 678 2730
  Email theresa.morton@bsmht.nhs.uk
Date applied 07/09/2005
Last edited 07/10/2009
Date ISRCTN assigned 13/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central